The patents protect key components of Direvo’s protein/strain engineering platform. Using this platform, Direvo develops products both independently and with global leaders such as AstraZeneca/MedImmune and Pfizer, as well as Danisco/Genencor and Nestle.
Thomas von Ruden, CEO of Direvo, said: “This is a very important milestone for the company, because Direvo now owns essential parts of intellectual property protecting its technology. This will give us much greater flexibility in the company’s future corporate development. It will allow us to spin out legal entities able to focus and further develop and customize the technology in their own markets.”